Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases
involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory
microenvironment.